Experimental and Clinical Psychology 2015;23(6):422-427. [doi: 10.1037/pha0000047]
Mary Rose Mamey, Celestina Barbosa-Leiker, PhD, Sterling McPherson, PhD, G. Leonard Burns, PhD, Craig Parks, PhD, John M. Roll, PhD (all from Washington State University, PN Node).
Researchers often want to examine two comorbid conditions simultaneously. One strategy to do so is through the use of parallel latent growth curve modeling (LGCM). This statistical technique allows for the simultaneous evaluation of two disorders to determine the explanations and predictors of change over time. Additionally, a piecewise model can help identify whether there are more than two growth processes within each disorder (e.g., during a clinical trial). A parallel piecewise LGCM was applied to self-reported attention-deficit/hyperactivity disorder (ADHD) and self-reported substance use symptoms in 303 adolescents enrolled in cognitive-behavioral therapy treatment for a substance use disorder and receiving either oral-methylphenidate or placebo for ADHD across 16 weeks (protocol CTN-0028). Assessing these two disorders concurrently allowed us to determine whether elevated levels of one disorder predicted elevated levels or increased risk of the other disorder. First, a piecewise growth model measured ADHD and substance use separately. Next, a parallel piecewise LGCM was used to estimate the regressions across disorders to determine whether higher scores at baseline of the disorders (i.e., ADHD or substance use disorder) predicted rates of change in the related disorder. Finally, treatment was added to the model to predict change.
Conclusions: While the analyses revealed no significant relationships across disorders, this study explains and applies a parallel piecewise growth model to examine the developmental processes of comorbid conditions over the course of a clinical trial. Strengths of piecewise and parallel LGCMs for other addictions researchers interested in examining dual processes over time are discussed. (Article (Peer-Reviewed), PDF, English, 2015)
Keywords: Adolescents | Attention Deficit Hyperactivity Disorder (ADHD) | Behavior therapy | Co-occurring disorders| CTN platform/ancillary study | Osmotic-Release Methylphenidate (OROS-MPH) | Pharmacological therapy | Experimental and Clinical Psychology (journal)
Document No: 1172, PMID: 26389639, PMCID: PMC4658254.
Submitted by Jack Blaine, MD, NIDA CCTN, 10/1/2015.